Hasil Pencarian  ::  Simpan CSV :: Kembali

"Latar belakang : Kanker kolorektal merupakan salah satu kanker dengan peningkatan insidensi yang paling pesat dalam dekade terakhir. Peningkatan terbesar diperkirakan akan terjadi di negara berkembang akibat perubahan gaya hidup. Pilihan tata laksana kanker kolorektal yang ada saat ini, seperti pembedahan, terapi radiasi, dan kemoterapi, diketahui belum mampu memberikan efek yang diinginkan. Dengan mempertimbangkan ketersediaan, harga, dan efek toksik, kedelai merupakan salah satu bahan pangan yang berpotensi menjadi terapi adjuvan. Hal ini dikarenakan zat aktif yang terkandung dalam kedelai, yaitu protein lunasin, diketahui memiliki efek antiinflamasi dan antikanker yang bermanfaat pada kasus kanker kolorektal.Metode : Sebanyak 30 ekor mencit Swiss Webster dipisahkan menjadi enam kelompok. Lima dari enam kelompok mencit diinduksi dengan azoksimetan (AOM) dan dekstran sodium sulfat (DSS). Ekstrak kedelai kaya lunasin dengan dosis 250 mg/kgBB, 300 mg/kgBB, dan 350 mg/kgBB diberikan pada tiga kelompok mencit selama 6 minggu. Pewarnaan imunohistokimia terhadap COX-2 kemudian dilakukan pada jaringan kolon distal mencit yang telah dikorbankan, lalu diamati di bawah mikroskop. Hasil interpretasi ekspresi COX-2 dinyatakan dalam bentuk optical density score (ODS).Hasil : Terdapat perbedaan yang signifikan antara kelompok negatif dengan kelompok intervensi ekstrak kedelai kaya lunasin pada dosis 300 mg/kgBB (p=0,047) dan 350 mg/kgBB (p=0,016).Kesimpulan : Pemberian ekstrak kedelai kaya lunasin menghambat ekspresi COX-2 pada sel epitel kripta kolon distal mencit yang diinduksi AOM dan DSS.

---

Background : Colorectal cancer is one of the fastest growing incidences of cancer in the past decade. The highest increase is expected to occur in developing countries due to lifestyle changes. The choice of colorectal cancer management currently available, such as surgery, radiation therapy, and chemotherapy, is known to have not been able to give the desired effect. Taking into account the availability, price and toxic effects, soybeans are one of the food ingredients that have the potential to become adjuvant therapy. This is because the active substance contained in soybeans, namely lunasin protein, is known to have anti-inflammatory and anticancer effects that are beneficial in colorectal cancer cases.

Method : A total of 30 Swiss Webster mice were separated into six groups. Five of the six groups of mice were induced with azoximethane (AOM) and dextran sodium sulfate (DSS). Extracts of lunasin-rich soybean with a dose of 250 mg / kgBB, 300 mg / kgBW, and 350 mg / kgBB were given to three groups of mice for 6 weeks. Immunohistochemical staining of COX-2 was then carried out on the distal colon tissue of mice that had been sacrificed, then observed under a microscope. The results of interpretation of COX-2 expression are stated in the form of optical density score (ODS).

Result : There was a significant difference between the negative group and the intervention group of lunasin-rich soybean extract at a dose of 300 mg/kgBW (p = 0.047) and 350 mg/kgBW (p = 0.016).

Conclusion : Administration of lunasin-rich soy extracts inhibit COX-2 expression in cryptic epithelial cells of distal colon of mice induced by AOM and DSS."

"This book is about Nutraceuticals in cancer therapy, specifically targeted and Adjuvant therapy. It shows several approaches for possibly reducing systemic toxicity. This book illustrates the role of several dietary agents, collectively called nutraceuticals or natural agents in the prevention and/or treatment of human malignancies known to be mediated through alterations in multiple molecular targets. This book contains sixteen chapters which begin with historical perspective on the value of natural agents in the prevention of human malignancies followed by a series of current topics on multiple nutraceuticals targeting multiple cancers. This collection would likely be useful for bringing newer generations with broader perspectives in launching cutting-edge innovative molecular research, which would certainly help in designing targeted clinical trials in order to realize the dream of customize strategies for the prevention and/or treatment of human malignancies without causing any systemic toxicity. Moreover, the knowledge gained would allow novel utilization of nutraceuticals as adjunct to both conventional chemotherapy and radiation therapy in order to improve the overall quality of life and survival of patients diagnosed with cancers."

"Latar belakang: Kedelai (Glycine max (L.) Merr.) merupakan tanaman yang sedang dikembangkan aktivitasnya sebagai antikanker. Salah satu senyawa aktifnya adalah Lunasin. Permasalahannya harga lunasin komersial sangat mahal karena biaya sintesis lunasin yang besar dan lama. Pada penelitian ini akan dikembangkan sediaan ekstrak tertarget Lunasin (ET-Lun) dengan tujuan untuk membuktikan aktivitas antikanker payudara ET-Lun secara in silico dan in vivo.Metode: Uji In silico, senyawa aktif pada kedelai sebagai ligan dilihat ikatannya terhadap protein ERα, ERβ, HER2, dan EGFR. Pengujian in vivo dibagi menjadi 2 kelompok besar yaitu kelompok kuratif dan preventif. Pada kelompok kuratif, tikus SD diinduksi dengan DMBA 20 mg/kg BB sebanyak 11 kali, 2 kali dalam seminggu kecuali kontrol normal (NOR). Setelah terbentuk nodul dengan volume 1-2 cm3, tikus diberikan perlakuan selama 8 minggu dengan tamoksifen 10 mg/kg BB (TAM), ET-Lun 500 mg/kg BB (ET- Lun), kombinasi ET-Lun dan tamoksifen (ADJ). Pada kelompok kontrol negatif (DMBA) pertumbuhan tumor diamati selama 8 minggu. Kelompok preventif (PREV), diberikan ET-Lun 1 minggu sebelum, selama, dan setelah induksi DMBA selama 24 minggu. Setelah perlakuan, tikus diterminasi, dan diambil tumornya. Volume tumor diukur, dan dilakukan pemeriksaan eskpresi ERα, ERβ, HER2, dan EGFR secara imunohistokimia dan qPCR.Hasil: Uji in silico menunjukkan Genistein dan Lunasin mempunyai afinitas terbesar terhadap ERα, ERβ, dan EGFR. Uji in vivo menunjukkan ET-Lun kelompok preventif dapat menekan pertumbuhan tumor sebesar 80%, sedangkan kelompok kuratif, terjadi perlambatan pertumbuhan tumor dibandingkan kelompok DMBA yaitu 0,31 kali pada kelompok ET-Lun; 0,37 kali pada tamoksifen; dan 0,15 kali pada kelompok adjuvan selama 8 minggu perlakuan. Secara molekuler, ET-Lun kelompok preventif dan kuratif dapat menurunkan ekspresi protein dan mRNA ERα, serta ekspresi protein EGFR jika dibandingkan kelompok DMBA. Kesimpulan: ET-Lun berpotensi sebagai kandidat antikanker pada pencegahan dan perlambatan karsinogenesis payudara tikus SD yang diinduksi DMBA.

---

Background: Soybean (Glycine max (L.) Merr.) is a plant that is being developed for its anticancer activity. One of the active compounds is Lunasin. The problem is that the price of commercial lunasin is very expensive because of the high cost of synthesizing lunasin and it takes a long time. In this study, the soybean extract with targeted lunasin (ET-Lun) will be developed with the aim of proving the anti-breast cancer activity of ET-Lun in silico and in vivo.

Method: In silico study, the active compounds in soybean as a ligand was seen for their binding to ERα, ERβ, HER2, and EGFR. In vivo assay, the rat was randomized into 2 major groups, namely curative and preventive groups. In the curative group, the SD rats were induced with DMBA 20 mg/kg BW 11 times, 2 times a week, except for normal controls (NOR). After forming nodules with a volume of 1-2 cm3, the rats were treated with tamoxifen 10 mg/kg BW (TAM), ET-Lun 500 mg/kg BW (ET-Lun), a combination of ET-Lun and tamoxifen (ADJ), for 8 weeks. For negative controls (DMBA), tumor growth in rats was observed in 8 weeks. In the preventive group (PREV), was given ET- Lun 1 week before, during, and after DMBA induction for 24 weeks. After treatment, all the rats were terminated, and the tumors were taken. Tumor volume was measured, and ERα, ERβ, HER2, and EGFR expression were examined by immunohistochemistry and qPCR.

Results: In silico study showed the Genistein and Lunasin had the greatest affinity for ERα, ERβ, and EGFR. In vivo study showed ET-Lun in the preventive group could suppress tumor growth by 80%, while in the curative group, ET-Lun could delay tumor growth by 0,31 times DMBA, tamoxifen 0,37 times DMBA, and adjuvant group 0,15 times DMBA, in 8 weeks of treatment. Molecularly, ET-Lun in the preventive and curative group, could decrease the expression of ERα protein and mRNA, as well as the expression of EGFR protein when compared to the DMBA group. Conclusion: ET-Lun has potential as an anticancer candidate for the prevention and delays of tumor growth in the DMBA-induced breast cancer rat model."